Commentary
Video
Author(s):
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on biomarker testing in metastatic or resectable non–small cell lung cancer.
China’s NMPA Grants Breakthrough Therapy Designation to Savolitinib Plus Osimertinib in EGFR+ NSCLC
Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD
Targeting PIK3CA With Allosteric Inhibitors Is Promising New Approach in Breast Cancer
Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD
FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer
FDA Grants Accelerated Approval to Zenocutuzumab for NRG1+ NSCLC and Pancreatic Adenocarcinoma
Palbociclib Plus Anti-HER2 and Endocrine Therapy Prolongs PFS in HR+/HER2+ Breast Cancer
Unveiling the Latest in HER2+ Breast Cancer and Beyond With Drs Sara Hurvitz and Neil Iyengar
Tamoxifen Reduces Ipsilateral Breast Recurrence in Good-Risk Ductal CIS
Real-World OS Outcomes Are Similar for Frontline CDK4/6 Inhibitor Combos in HR+, HER2– Breast Cancer